Targeting a specific type of kidney cancer with new therapies
Official title: Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma
Funded at University of California-Irvine · NIH-11003694 · Data updated 2026-11-12
This study is looking for new ways to treat clear cell kidney cancer by testing special drugs that could help target cancer cells with a specific mutation, aiming to offer better options for patients who are facing this tough condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $209,646 |
| NIH project number | 5R21CA280564-02 |
| Project ID | NIH-11003694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with VHL-deficient clear cell renal cell carcinoma who have not responded well to existing therapies.
✕Less likely to help
Patients with other types of kidney cancer or those whose tumors do not have VHL mutations may not benefit from this research.
What this research studies
This research focuses on developing new treatments for clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that often resists current therapies. The approach utilizes synthetic lethality screens to identify compounds that can selectively kill cancer cells with a specific mutation while sparing normal cells. The study aims to investigate the effectiveness of cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, in targeting VHL-deficient ccRCCs. If successful, these therapies could lead to improved treatment options for patients with this challenging cancer.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options for patients with VHL-deficient clear cell renal cell carcinoma.
How similar studies have gone: Other research has shown promise in using synthetic lethality approaches for cancer treatment, indicating potential success for this novel strategy.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Razorenova, Olga V — University of California-Irvine
- Study coordinator: Razorenova, Olga V
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.